From Huntington Study Group: Prilenia Therapeutics B.V., a clinical stage biotechnology company, met a milestone that the last participant in PROOF-HD, a global Phase 3 study in Huntington’s disease (HD), has completed the last planned visit of the blinded treatment period, marking the completion of the main study. Topline results of the PROOF-HD study are expected in early Q2 2023.
Check out their post to learn more about the study: https://www.prilenia.com/prilenia-achieves-last-patient-last-visit-in-phase3-proof-hd